Spots Global Cancer Trial Database for Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Official Title: Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Study ID: NCT02644369
Interventions
Study Description
Brief Summary: This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment. Pembrolizumab is a monoclonal antibody that is designed to block a protein called programmed cell death 1 ligand 1 (PD-L1) which will allow the body's immune system to kill the cancer cells.
Detailed Description: This study will involve treatment with pembrolizumab, tests and procedures done for safety, and the collection of archival tumor tissue, fresh tumor biopsies, and blood samples for biomarker research (including genetic testing).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact Details
Name: Lillian Siu, M.D.
Affiliation: Princess Margaret Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
